文献速递腹部技术与安全CT

RECIST 1.1、Choi和mChoi标准评估瑞戈非尼联合抗PD-1抗体治疗转移性结直肠癌患者肿瘤反应

RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody.
PubMed 文献 · Eur J Radiol · 2021-06-10

回顾性纳入单中心23例接受瑞戈非尼联合抗PD-1抗体治疗的转移性结直肠癌患者,用RECIST 1.1、Choi和mChoi标准评估基线和首次增强CT肿瘤反应,以总生存为终点。三种标准均显示非进展患者总生存显著优于进展患者;Choi标准识别的缓解者总生存优于非缓解者但未达统计学显著(P=0.262)。

要点

  • RECIST 1.1、Choi和mChoi标准均能识别瑞戈非尼联合抗PD-1抗体治疗mCRC患者的生存获益。
  • 按RECIST 1.1,8例(34.8%)为稳定疾病,15例(65.2%)为进展疾病。
  • 按Choi和mChoi,分别有5例(21.7%)和1例(4.3%)为缓解者。

核心结论

  • RECIST 1.1、Choi和mChoi标准均可识别瑞戈非尼联合抗PD-1抗体治疗mCRC患者的生存获益,但Choi标准识别的缓解者价值尚需进一步研究验证。

研究设计与样本

  • 单中心回顾性研究,纳入23例接受瑞戈非尼联合抗PD-1抗体治疗的转移性结直肠癌患者,采用增强CT评估基线和首次肿瘤评估,比较RECIST 1.1、Choi和mChoi三种标准,以总生存为终点事件。

诊断标准与关键数值

  • RECIST 1.1标准:8例(34.8%)为稳定疾病(SD),15例(65.2%)为进展疾病(PD)。
  • Choi标准:5例(21.7%)为缓解者。
  • mChoi标准:1例(4.3%)为缓解者。

临床应用与阅片要点

  • 三种标准均显示非进展患者总生存显著优于进展患者。
  • Choi标准识别的缓解者总生存优于非缓解者,但未达统计学显著(P=0.262)。
  • Choi标准识别的缓解者价值尚需进一步研究验证。

局限性

  • Choi标准识别的缓解者价值尚需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: No comparative study on evaluating performance of radiological criteria has been investigated in metastatic colorectal cancer (mCRC) patients treated with the combination of Regorafenib and anti-programmed cell death 1(PD-1) antibody. We aimed to compare the performance of different radiological criteria in evaluating response in mCRC patients treated with the combination of Regorafenib plus anti-PD-1 antibody.

METHOD: We retrospectively recruited patients treated with Regorafenib and anti-PD-1 antibody in a single institution. Baseline and the first tumor evaluation of contrast-enhanced computed tomography (CE-CT) were assessed by three evaluation criteria: RECIST 1.1, Choi, modified Choi (mChoi). Overall survival (OS) was defined as endpoint event.

RESULTS: Twenty-three mCRC patients [age: 58.8 ± 10.6 years, 18 (78.3 %) males] were assessed. The median overall survival was 11.8 months. According to RECIST 1.1, 8 (34.8 %) patients were stable disease (SD) and 15 (65.2 %) were progressive disease (PD). According to Choi and mChoi, 5 (21.7 %) and 1(4.3 %) patient was responders, respectively. All non-PD patients showed significantly better overall survival than PD patients by all criteria. According to Choi, those identified as responders showed better overall survival than non-responders though significant statistics were not reached (P=0.262).

CONCLUSIONS: RECIST 1.1, Choi and mChoi criteria could identify survival benefit from Regorafenib plus anti-PD-1 antibody in mCRC patients. However, the value of responders detected by Choi remains to be validated in further studies.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Li L, Xu Y, Yang Y, et al. RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody. Eur J Radiol. 2021. PMID: 34146911. doi:10.1016/j.ejrad.2021.109823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。